Literature DB >> 23744806

Lymph node management in patients with paratesticular rhabdomyosarcoma: a population-based analysis.

Nguyen D Dang1, Phuong-Thanh Dang, Jason Samuelian, Arnold C Paulino.   

Abstract

BACKGROUND: Paratesticular rhabdomyosarcoma (PTRMS) is the most common primary solid tumor arising from the mesenchymal tissue of the testis. Traditionally, retroperitoneal lymph node dissection is not recommended for children aged <10 years because of the morbidity of the procedure and low risk of retroperitoneal lymph node involvement. In the current study, the authors analyzed the patient and tumor characteristics of PTRMS as well as survival outcomes associated with lymph node dissection status.
METHODS: A total of 255 cases of PTRMS were identified from the patient data reported by the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute from 1973 through 2009.
RESULTS: Among 173 patients aged ≥ 10 years, lymph node dissection was found to improve the 5-year overall survival (OS) rate from 64% to 86% (P  <  0.01). Conversely, patients aged <10 years fared extremely well regardless of lymph node dissection status; the 5-year OS rate was 100% and 97%, respectively, for patients who did versus those who did not undergo lymph node dissection (P  = .37). The yield of positive lymph nodes was approximately ≥  20% when <  11 lymph nodes were removed. The incidence of lymph node involvement was also higher in older patients compared with younger patients (40% vs 8%). Radiotherapy improved the OS rate in patients with lymph node involvement (5-year OS rate: 90% with vs 36% without radiation; P < .0001).
CONCLUSIONS: Lymph node dissection is recommended in patients aged ≥10 years. Radiotherapy is beneficial in patients with lymph node-positive disease.
Copyright © 2013 American Cancer Society.

Entities:  

Keywords:  lymph node dissection; paratesticular rhabdomyosarcoma; pediatric cancer; soft-tissue sarcoma

Mesh:

Year:  2013        PMID: 23744806     DOI: 10.1002/cncr.28198

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

1.  Primary tumor size predicts pathologic findings in the retroperitoneal lymph nodes in patients with paratesticular rhabdomyosarcoma.

Authors:  Shaheen Alanee; Bradley Holland; Danuta Dynda; Onsi Kamel; Sabha Ganai
Journal:  Virchows Arch       Date:  2014-10-08       Impact factor: 4.064

2.  Spontaneous Rupture of Rhabdomyosarcoma of the Testis With Unilateral Ptosis: A Case Report and Literature Review.

Authors:  Ronghua Wu; Xing Liu; Yajun Song; Shanhong Yi; Wei Chen; Wanlei Fu; Jingzhen Zhu
Journal:  Front Pediatr       Date:  2022-06-28       Impact factor: 3.569

Review 3.  What is new in the biology and treatment of pediatric rhabdomyosarcoma?

Authors:  Douglas S Hawkins; Abha A Gupta; Erin R Rudzinski
Journal:  Curr Opin Pediatr       Date:  2014-02       Impact factor: 2.856

4.  Demographic and Treatment Variables Influencing Outcome for Localized Paratesticular Rhabdomyosarcoma: Results From a Pooled Analysis of North American and European Cooperative Groups.

Authors:  David O Walterhouse; Donald A Barkauskas; David Hall; Andrea Ferrari; Gian Luca De Salvo; Ewa Koscielniak; Michael C G Stevens; Hélène Martelli; Guido Seitz; David A Rodeberg; Margarett Shnorhavorian; Roshni Dasgupta; John C Breneman; James R Anderson; Christophe Bergeron; Gianni Bisogno; William H Meyer; Douglas S Hawkins; Veronique Minard-Colin
Journal:  J Clin Oncol       Date:  2018-10-23       Impact factor: 44.544

Review 5.  Current management of pediatric soft tissue sarcomas.

Authors:  Surasak Sangkhathat
Journal:  World J Clin Pediatr       Date:  2015-11-08

6.  Surgical management of paratesticular rhabdomyosarcoma: A consensus opinion from the Children's Oncology Group, European paediatric Soft tissue sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe.

Authors:  Timothy N Rogers; Guido Seitz; Jörg Fuchs; Helene Martelli; Roshni Dasgupta; Jonathan C Routh; Douglas S Hawkins; Ewa Koscielniak; Gianni Bisogno; David A Rodeberg
Journal:  Pediatr Blood Cancer       Date:  2021-02-01       Impact factor: 3.838

Review 7.  Recent advances in understanding and managing rhabdomyosarcoma.

Authors:  Susan M Hiniker; Sarah S Donaldson
Journal:  F1000Prime Rep       Date:  2015-05-12

Review 8.  Pediatric genitourinary oncology.

Authors:  Francisco Tibor Dénes; Ricardo Jordão Duarte; Lílian Maria Cristófani; Roberto Iglesias Lopes
Journal:  Front Pediatr       Date:  2013-12-16       Impact factor: 3.418

9.  Impact of local control and surgical lymph node evaluation in localized paratesticular rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee.

Authors:  Jonathan C Routh; Roshni Dasgupta; Yueh-Yun Chi; Margarett Shnorhavorian; Jing Tian; David O Walterhouse; John Breneman; Suzanne L Wolden; Carola A Arndt; Douglas S Hawkins; David A Rodeberg
Journal:  Int J Cancer       Date:  2020-07-11       Impact factor: 7.396

10.  An Adult Case of Paratesticular Spindle Cell Rhabdomyosarcoma.

Authors:  Joan C Delto; George F Wayne; Sofia Garces; Ana M Medina; Alan M Nieder
Journal:  Urol Case Rep       Date:  2014-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.